Template
ADHD, follow-up
Tap a choice or type a Repertoire Line to see how the note changes. Defaults are what the template inserts on its own.
Practice wording only: leave out patient details. Nothing typed here is saved or sent.
MonthChoose anyFirst line
StatusChoose oneFirst line
Rating scalesChoose one
AdherenceChoose one
Side effectsChoose any
Growth and vitalsChoose one
MonitoringChoose any
Side-effect planChoose any
Medication planChoose one
RefillsChoose one
Behavioral and school supportsChoose any
Adolescent counselingChoose any
Additional counselingChoose any
ReferralChoose any
Follow-upChoose one
Closing
Family to call with side effects or concerns before the next visit. Caregiver expressed understanding and agreement with plan. Answered all questions.
What the sources cover
- Month-year lead
- Doing great or doing well or improving or not as well or struggling
- Parent and teacher rating scales (Vanderbilts) stable or improved or worse or not returned
- Growth monitoring (stimulants reduce growth velocity)
- HR and BP monitoring on stimulants
- Weight down since last visit
- BP or HR elevated, will recheck
- Prescription drug monitoring program reviewed
- Decreased appetite
- Trouble sleeping
Show 30 more
- Irritability or moodiness (incl. preschool mood lability)
- Guanfacine/clonidine somnolence, dizziness, low BP/HR
- Taper guanfacine/clonidine rather than stopping abruptly
- Continue current medication and dose
- Increase dose for persistent symptoms
- Decrease dose for side effects
- Switch medication (other stimulant class; ~40% respond to only one class)
- Add a short-acting afternoon dose
- Add extended-release guanfacine or clonidine as an adjunct
- Medication names
- Continue behavioral therapy
- Recommended parent training in behavior management
- Recommended school-skills or organizational training
- Recommended requesting a 504 plan or IEP evaluation
- Continue current 504 plan or IEP
- Safe storage, not sharing medication (diversion)
- Medication coverage while driving
- Substance use screening
- Transition to adult care from about age 14
- Refer to psychiatry
- Refer to psychology or therapy
- Refer to developmental-behavioral pediatrics
- Follow up in 1 month (after a change)
- Family education: dose or drug changes may be needed and take a few months; monitor at regular intervals
- Adherence: daily or school days only or missing doses
- No chest pain, fainting or palpitations
- Atomoxetine mood and suicidal-thought monitoring
- Depression screen reviewed (adolescents)
- Phone check 1–2 weeks after a dose change
- Patient agrees with the plan
Used to decide, kept out of the note
- Pharmacogenetic testing not recommended
- Unproven treatments (diet, neurofeedback, CBD, eTNS, mindfulness, cognitive training)
Sources
- Wolraich ML et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.…
- Cribsiders #13, All That Fidgets is Not ADHD (November 25, 2020; Sarah Vinson, MD)
- Barbaresi WJ et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with…